Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia 23Myelodysplastic Syndromes 22Leukemia, Myeloid, Acute 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Non-Hodgkin 17Multiple Myeloma 15Lymphoma 14Hodgkin Disease 13Leukemia, Lymphocytic, Chronic, B-Cell 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Lymphoma, Mantle-Cell 10Lymphoma, Follicular 10Congenital Abnormalities 10Lymphoma, B-Cell, Marginal Zone 9Burkitt Lymphoma 9Lymphoma, Large B-Cell, Diffuse 8Anemia, Refractory, with Excess of Blasts 8Neoplasms, Plasma Cell 7Myeloproliferative Disorders 7Hematologic Neoplasms 7Lymphoma, Large-Cell, Immunoblastic 6Leukemia, Myeloid, Accelerated Phase 6Blast Crisis 6Primary Myelofibrosis 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myelomonocytic, Chronic 5Graft vs Host Disease 5Sezary Syndrome 4Mycosis Fungoides 4

Interventions

Gemcitabine 34pembrolizumab 27Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Whole-Body Irradiation × Clear all
NCT01871441 2025-05-16

Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Thomas Jefferson University

Phase 2 Terminated
4 enrolled 10 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡